Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Dow
Moodys
Merck
AstraZeneca

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

ATROVENT HFA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Atrovent Hfa patents expire, and what generic alternatives are available?

Atrovent Hfa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-nine patent family members in thirty-eight countries.

The generic ingredient in ATROVENT HFA is ipratropium bromide. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.

Drug patent expirations by year for ATROVENT HFA
Drug Prices for ATROVENT HFA

See drug prices for ATROVENT HFA

Drug Sales Revenue Trends for ATROVENT HFA

See drug sales revenues for ATROVENT HFA

Recent Clinical Trials for ATROVENT HFA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Simbec ResearchPhase 1
AstraZenecaPhase 1
London Health Sciences CentrePhase 2

See all ATROVENT HFA clinical trials

Pharmacology for ATROVENT HFA
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists
Synonyms for ATROVENT HFA
(1R,3r,5S)-3-(3-hydroxy-2-phenylpropanoyloxy)-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane bromide
(1R,5S)-3-((3-hydroxy-2-phenylpropanoyl)oxy)-8-isopropyl-8-methyl-8-azabicyclo[3.2.1]octan-8-ium bromide
(1S,3S,5R)-3-Tropyloxy-8-isopropyltropanium bromide
(3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane bromide
(8r)-3-alpha-Hydroxy-8-isopropyl-1-alpha-H,5-alpha-H-tropiumbromide-(+-)-tropate
(endo,Anti)-(1)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
(endo,syn)-(+-)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
(endo,syn)-(+/-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
(exo,Syn)-(1)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
1-alpha-H,5-alpha-H-Tropanium, 3-alpha-hydroxy-8-isopropyl-, bromide, (+-)-tropate
22254-24-6
22254-36-0
24358-20-1
3-alpha-Hydroxy-8-isopropyl-1-alpha-H,5-alpha-H-tropanium bromide (+-)-tropate
3alpha-hydroxy-8-isopropyl-1alphaH,5alphaH-tropanium bromide (+-)-tropate
3alpha-hydroxy-8-isopropyl-1alphaH,5alphaH-tropanium bromide (+/-)-tropate
58073-59-9
60205-81-4 (Parent)
60251-88-9
8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, endo-
8-Isopropylnoratropine methobromide
AKOS015895324
AKOS016013651
AKOS027301349
AKOS030485952
ATEM
ATROPINE ISOPROPYLBROMIDE
Atrovent
BC677124
BDBM50021892
Bromure d'ipratropium
Bromure d'ipratropium [INN-French]
Bromuro de ipratropio
Bromuro de ipratropio [INN-Spanish]
C20H30BrNO3
CHEBI:46659
CHEMBL1464005
DB00332
DTXSID60858923
EINECS 244-873-8
EINECS 246-197-9
EINECS 261-098-0
EINECS 262-128-5
endo-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
HMS2234J05
Ipratropii bromidum
Ipratropii bromidum [INN-Latin]
ipratropium bromide
Ipratropium Bromide (anhydrous)
Ipratropium bromide [INN]
Ipratropium bromide anhydrous
Ipratropium bromide monohydrate
Ipratropium Bromide'
Ipratropiumbromid
Ipratropiumbromid [German]
Itrop
MLS000069557
MolPort-006-069-092
MolPort-027-946-829
MolPort-035-924-120
N-Isopropylnoratropinium bromomethylate
N-Isopropylnortropine tropate methobromide
Opera_ID_1621
Prestwick_279
REGID_for_CID_657308
SC-14062
Sch 1000
SCHEMBL107906
SCHEMBL16762661
SCHEMBL3852
SCHEMBL3854
SMR000058764
UNII-VJV4X1P2Z1
VJV4X1P2Z1

US Patents and Regulatory Information for ATROVENT HFA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ATROVENT HFA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
McKinsey
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.